In conclusion, the clinical and the functional data we show here support that targeting the MEK5/ERK5 route may represent a novel therapeutically relevant strategy worth being explored in lung cancer, particularly in combination with standard of care drugs. Here, MAP2K5 is linked to lung cancer.